BACKGROUND: Previous retrospective or observational series suggest that many @entity1 with an @entity737 ( @entity737 ) will be treated with @entity734 ( @entity734 ) to modify the frequency or manifestation of recurrent @entity943 . The relative clinical benefit, however, is uncertain, and deleterious interactions can occur. The objective of this clinical investigation was to study the need for, and effects of, concomitant AAD use with the @entity737 in a prospectively defined cohort. METHODS: All @entity1 randomly assigned to the @entity737 arm of the @entity2132 ( @entity2132 ) study were followed for the addition of class I or III @entity734 ("crossover") after hospital discharge. Addition of @entity734 was strictly regulated by @entity2132 protocol. The timing and reasons for crossover and the effects on @entity943 recurrence were analyzed. @entity1 were excluded if they required @entity734 before hospital discharge after index @entity943 or if they had no @entity943 before initiation of @entity734 . RESULTS: After a median follow-up of 135 days, 81 (18%) of the 461 eligible @entity1 required @entity734 and formed the crossover group. The primary reason for crossover was frequent @entity1457 in 64% of @entity1 . The most common AAD selected was @entity2643 (in 42%). Independent predictors of crossover were lower ejection fraction, absence of @entity2224 , or presence of nonsyncopal @entity1165 at presentation, prior unexplained @entity1163 , female sex, and history of cigarette smoking. Before AAD use, the 1-year @entity943 event rate was 90%; after AAD, the event rate was only 64% (P =.0001). The time to first event was extended from 3.9 +/- 0.7 months to 11.2 +/- 1.8 months. There were 1.4 +/- 3.7 fewer @entity737 therapy events (P =.005) after crossover, predominantly accounted for by reduction in shocks rather than antitachycardia pacing therapies. CONCLUSIONS: The majority of @entity1 who receive ICDs for sustained @entity1165 or @entity2224 can be treated without @entity734 . Most commonly, @entity734 are added to combat frequent @entity1457 , which are successfully reduced by AAD therapy.

Antiarrhythmic drug use in the implantable defibrillator arm of the XXXX ( @entity2132 ) Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia'] @entity1457 :: ('MESH:D012769', 'Disease') :: ['ICD shocks'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope'] @entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter-defibrillator'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['Antiarrhythmics Versus Implantable Defibrillators', 'AVID'] @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation'] @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia', 'ventricular arrhythmias', 'arrhythmias', 'arrhythmia'] @entity734 :: ('MESH:D019966', 'Disease') :: ['AADs', 'antiarrhythmic drugs']
@entity2132 :: (MESH:D006086,Disease) :: ['Antiarrhythmics Versus Implantable Defibrillators']
